Travere Therapeutics, Inc. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was FILSPARI at $200.2 million, 89% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
651
|
225
|
170
|
127
|
130
|
165
|
114
|
82
|
75
|
| FILSPARI |
550
+104.9%
share 84.4%
|
200
+120.2%
share 89.1%
|
141
+96.2%
share 83.2%
|
105
+88.2%
share 82.7%
|
103
+108.2%
share 79.7%
|
91
share 55.1%
|
72
share 62.8%
|
56
share 68.4%
|
50
share 66.4%
|
| Tiopronin Products |
83
-7.0%
share 12.7%
|
20
-10.1%
share 8.9%
|
20
-11.7%
share 12.0%
|
19
-3.2%
share 15.2%
|
23
-2.6%
share 17.9%
|
22
share 13.5%
|
23
share 20.1%
|
20
share 24.4%
|
24
share 32.0%
|
| License |
18
-76.6%
share 2.8%
|
4
-91.6%
share 1.9%
|
8
-58.0%
share 4.9%
|
3
-53.9%
share 2.1%
|
3
+148.3%
share 2.4%
|
52
share 31.4%
|
20
share 17.1%
|
6
share 7.2%
|
1
share 1.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TVTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1438533
- Former names
- Retrophin, Inc. (until Nov 13, 2020); Desert Gateway, Inc. (until Feb 19, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.